Effects of ropinirole on various Parkinsonian models in mice, rats, and cynomolgus monkeys

Pharmacology Biochemistry and Behavior

Volumn 65, Issue 3, 2000, Pages 503-508

  Fukuzaki, Koichiro ^a   Kamenosono, Takeshi ^a   Nagata, Ryoichi ^a  

^a SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

Bromocriptine; Catalepsy; Cynomolgus monkeys; L DOPA; Mice; Parkinson's disease; Rats; Ropinirole; Tremor; Ventromedial tegmentum

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; OXIDOPAMINE; OXOTREMORINE; RESERPINE; ROPINIROLE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; MALE; MONKEY; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; BROMOCRIPTINE; CATALEPSY; DOPAMINE AGONISTS; INDOLES; MACACA FASCICULARIS; MALE; MICE; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RESERPINE; TREMOR;

EID: 0033953679     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00240-3     Document Type: Article

References (38)

1. Arnt J., Hyttel J. Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK&F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berlin). 85:1985;346-352.
2. 2 receptors of rat cerebral cortex. Gen. Pharmacol. 17:1986;57-62.
3. Bebbington A., Brimbelcombe R.W., Shakeshaft D. The central and peripheral activity of acetylenic amines related to oxotremorine. Br. J. Pharmacol. 26:1966;56-67.
4. 4,4 receptors in functional studies using microphysiometry. Br. J. Pharmacol. (Suppl.). 119:1997;346P.
5. Coward D.M., Doggett N.S., Sayers A.C. The pharmacology of N-carbamoyl-2-(2,6-dichlorophenyl)acetamidine hydrochloride (LON-954) a new tremorogenic agent. Arzneimittleforschung/Drug Res. 27:1977;2326-2332.
6. 2-receptor agonist. Br. J. Clin. Pharmacol. 32:1991;483-488.
7. Doggett N.S., O'Farrell S.A. Modification of oxotremorine tremor and hypothermia by injections of drugs into the cerebral ventricles of the mouse. Naunyn Schmiedebergs Arch. Pharmacol. 294:1976;149-155.
8. 2 agonist. Pharmacol. Biochem. Behav. 38:1991;147-154.
9. Fahn S. "On-Off" phenomenon with levo-dopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine Neurology. 24:1974;431-441.
10. Finney D.J. Probit analysis. 3rd ed:1971;Cambridge University Press, Cambridge, MA.
11. Goldstein M., Battista A.F., Ohmoto T., Anagnoste B., Fuxe K. Tremor and involuntary movements in monkeys. Effect of L-dopa and of a dopamine receptor stimulating agent Science. 179:1973;816-817.
12. 2 cortical receptors. Biol. Signals. 3:1994;223-229.
13. Herrera-Marschitz M., Ungerstedt U. Effect of the dopamine D-1 antagonist SCH 23390 on rotational behaviour induced by apomorphine and pergolide in 6-hydroxy-dopamine denervated rats. Eur. J. Pharmacol. 109:1985;349-354.
14. 3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res. 709:1996;259-264.
15. Iwata S., Nomoto M., Fukuda T. Effects of β-adrenergic blockers on drug-induced tremors. Pharmacol. Biochem. Behav. 44:1993;611-613.
16. 2 receptor stimulation in cynomolgus monkeys with unilateral lesions in the ventromedial tegmentum. Eur. J. Pharmacol. 319:1997;197-205.
17. König J.F.R., Klippel R.A. The rat brain, a stereotaxic atlas of the forebrain and lower parts of the brain stem. 1963;Robert E. Krieger Publishing Co. Inc, New York.
18. Korczyn A.D., Brooks D.J., Brunt E.R., Poewe W.H., Rascol O., Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease. A 6-month interim report of a 3-year study Mov. Disord. 13:1998;46-51.
19. Mackenzie, R. G.; Zigmond, M. J.: Chronic neuroleptic treatment with the Folin phenol reagent. J. Biol. Chem. 265-275; 1951.
20. McPherson G.A. In vitro selectivity of lisuride and other ergot derivatives for alpha 1- and alpha 2-adrenoceptors. Eur. J. Pharmacol. 97:1984;151-155.
21. 2 dopamine receptors in striatum and nucleus accumbens of rats chronically treated with haloperidol. Neuropharmacology. 26:1987;477-480.
22. Minami M., Nemoto M., Endo T., Hamaue N., Kohno Y. Effects of talipexole on emesis-related changes in abdominal afferent vagal activity and ileal serotonin metabolism in rats. Res. Commun. Mol. Pathol. Pharmacol. 95:1997;67-82.
23. Miyamoto T., Battista A., Goldstein M., Fuxe K. Long-lasting anti-tremor activity induced by 2-Br-a-ergocryptine in monkeys. J. Pharm. Pharmacol. 26:1974;452-454.
24. Nomoto M. Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals. Jpn. J. Psychopharmacol. 16:1996;113-122.
25. Ohye C., Imai S., Nakajima H., Shibazaki T., Hirai H. Experimental study of spontaneous postural tremor induced by a more successful tremor producing procedure in the monkey. Adv. Neurol. 24:1979;83.
26. Pahwa R., Koller W.C. Dopamine agonists in the treatment of Parkinson's disease. Cleve. Clin. J. Med. 62:1995;212-217.
27. Pearce R.K.B., Jackson M., Smith L., Jenner P., Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov. Disord. 10:1995;731-740.
28. Pearce R.K.B., Baneji T., Jenner P., Marsden C.D. Effects of repeated treatment with L-DOPA, bromocripitine and ropinirole in drug naive MPTP-treated common marmosets. Br. J. Pharmacol. (Suppl.). 118:1996;37P.
29. Pearce R.K.B., Baneji T., Jenner P., Marsden C.D. De novo adminidtration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov. Disord. 3:1998;234-241.
30. Poirier L.J., Sourkes T.L., Bouvier G., Boucher R., Carabin S. Striatal amines, experimental tremor and the effect of harmaline in the monkey. Brain. 89:1966;37-52.
31. 3H]SCH23390 binding sites increase after chronic blockade of D-1 dopamine receptors. Eur. J. Pharmacol. 118:1985;367-370.
32. Ramji, J.; Keogh, J; Taylor, A.; Filer, C.: Pharmacokinetics of ropinirole hydrochloride: Absorption, distribution, metabolism and excretion of ropinirole hydrochloride after single and repeat administration to rats and monkeys. Jpn. Pharmacol. Ther. 24: 1996.
33. Sibley D.R., Monsma F.J. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13:1992;61-69.
34. 3) as a target for neuroleptics. Nature. 347:1990;146.
35. 1. Nature. 350:1991;614-619.
36. Szabo J., Cowan W.M. A stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis). J. Comp. Neurol. 222:1984;265-300.
37. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24:1970;485-493.
38. 4 receptor with high affinity for dopamine the antipsychotic clozapine. Nature. 350:1991;610-614.